Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2301
Ampco-Pittsburgh
AP
$190M
| $1.61M | ﹤0.01% |
523,024
+22,400
| +4% | +$72K |
2013 Q2
28 quarters
|
|
|
RUTH
2302
DELISTED
Ruth's Hospitality Group, Inc.
RUTH
| $1.6M | ﹤0.01% |
196,400
+91,100
| +87% | +$794K |
2017 Q2
12 quarters
|
|
2303
Trimble
TRMB
$13.9B
| $1.6M | ﹤0.01% |
+37,000
| New | +$1.39M |
2020 Q2
0 quarters
|
|
|
TCFC
2304
DELISTED
The Community Financial Corporation Common Stock
TCFC
| $1.6M | ﹤0.01% |
65,468
-3,719
| -5% | -$81.8K |
2017 Q2
12 quarters
|
|
2305
Gold.com Inc
GOLD
$1.16B
| $1.6M | ﹤0.01% |
167,584
+110,984
| +196% | +$876K |
2018 Q4
6 quarters
|
|
|
MTL
2306
DELISTED
Mechel PAO American Depository Shares, each representing two ordinary shares (ADSs)
MTL
| $1.59M | ﹤0.01% |
925,270
+94,900
| +11% | +$166K |
2016 Q3
15 quarters
|
|
2307
Full House Resorts
FLL
$42.5M
| $1.59M | ﹤0.01% |
1,192,590
+29,999
| +3% | +$45.5K |
2013 Q4
26 quarters
|
|
2308
State Street SPDR S&P China ETF
GXC
$449M
| $1.58M | ﹤0.01% |
+15,100
| New | +$1.48M |
2020 Q2
0 quarters
|
|
2309
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $1.58M | ﹤0.01% |
9,416
-29,027
| -76% | -$3.13M |
2017 Q3
11 quarters
|
|
2310
Dianthus Therapeutics
DNTH
$4.58B
| $1.58M | ﹤0.01% |
13,144
+2,535
| +24% | +$357K |
2020 Q1
1 quarter
|
|
2311
Assembly Biosciences
ASMB
$470M
| $1.58M | ﹤0.01% |
5,637
+1,317
| +30% | +$307K |
2017 Q1
13 quarters
|
|
2312
Invesco Bloomberg Enhanced Fallen Angels ETF
IFLN
$291M
| $1.57M | ﹤0.01% |
86,809
+62,309
| +254% | +$1.1M |
2019 Q1
5 quarters
|
|
2313
Grupo SIMEC
SIM
| $1.57M | ﹤0.01% |
255,400
+600
| +0.2% | +$3.99K |
2013 Q2
28 quarters
|
|
2314
Norwood Financial Corp
NWFL
$368M
| $1.56M | ﹤0.01% |
62,875
+3,400
| +6% | +$80.7K |
2017 Q2
12 quarters
|
|
2315
Canadian Pacific Kansas City
CP
$75.3B
| $1.56M | ﹤0.01% |
30,500
-318,500
| -91% | -$15.1M |
2020 Q1
1 quarter
|
|
2316
Vince Holding Corp
VNCE
$149M
| $1.56M | ﹤0.01% |
280,452
-30,302
| -10% | -$168K |
2017 Q1
13 quarters
|
|
2317
IDEAYA Biosciences
IDYA
$3.49B
| $1.55M | ﹤0.01% |
+109,100
| New | +$860K |
2020 Q2
0 quarters
|
|
|
SLCT
2318
DELISTED
Select Bancorp, Inc.
SLCT
| $1.55M | ﹤0.01% |
190,375
+13,414
| +8% | +$101K |
2016 Q4
14 quarters
|
|
2319
Fluor
FLR
$6.68B
| $1.55M | ﹤0.01% |
128,000
-241,400
| -65% | -$2.53M |
2019 Q1
5 quarters
|
|
|
NEWR
2320
DELISTED
New Relic, Inc.
NEWR
| $1.54M | ﹤0.01% |
+22,400
| New | +$1.34M |
2020 Q2
0 quarters
|
|
2321
Regency Centers
REG
$13.2B
| $1.54M | ﹤0.01% |
33,525
-1,064,570
| -97% | -$45M |
2014 Q4
22 quarters
|
|
|
SVA
2322
DELISTED
Sinovac Biotech, Ltd
SVA
| $1.54M | ﹤0.01% |
2,375,841
| – | – |
2013 Q2
28 quarters
|
|
2323
HF Sinclair
DINO
$21.7B
| $1.53M | ﹤0.01% |
52,582
-312,276
| -86% | -$9.28M |
2017 Q4
10 quarters
|
|
|
AGFS
2324
DELISTED
AgroFresh Solutions Inc
AGFS
| $1.53M | ﹤0.01% |
506,433
+218,429
| +76% | +$541K |
2019 Q2
4 quarters
|
|
2325
KORU Medical Systems
KRMD
$135M
| $1.53M | ﹤0.01% |
170,500
+67,578
| +66% | +$683K |
2020 Q1
1 quarter
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.